Publication:
Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis

Thumbnail Image

Open/View Files

Date

2015

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Nature Pub. Group
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Miao, J., A. V. Ling, P. V. Manthena, M. E. Gearing, M. J. Graham, R. M. Crooke, K. J. Croce, et al. 2015. “Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis.” Nature Communications 6 (1): 6498. doi:10.1038/ncomms7498. http://dx.doi.org/10.1038/ncomms7498.

Research Data

Abstract

Despite the well-documented association between insulin resistance and cardiovascular disease, the key targets of insulin relevant to the development of cardiovascular disease are not known. Here, using non-biased profiling methods, we identify the enzyme flavin-containing monooxygenase 3 (Fmo3) to be a target of insulin. FMO3 produces trimethylamine N-oxide (TMAO), which has recently been suggested to promote atherosclerosis in mice and humans. We show that FMO3 is suppressed by insulin in vitro, increased in obese/insulin resistant male mice and increased in obese/insulin-resistant humans. Knockdown of FMO3 in insulin-resistant mice suppresses FoxO1, a central node for metabolic control, and entirely prevents the development of hyperglycaemia, hyperlipidemia and atherosclerosis. Taken together, these data indicate that FMO3 is required for FoxO1 expression and the development of metabolic dysfunction.

Description

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories